What is the current Price Target for the Pieris Pharmaceuticals, Inc. stock?

The average Pieris Pharmaceuticals, Inc. target price is $233.58. This is 69.06% higher than the current stock price. The highest price target is 105.20%, the lowest is 49.86%. 18 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2027 .

How high will the Pieris Pharmaceuticals, Inc. stock rise?

No reliable answer can be given as to how high the Pieris Pharmaceuticals, Inc. stock will rise. The performance of stocks, including the Pieris Pharmaceuticals, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Pieris Pharmaceuticals, Inc. stock today?

The performance of Pieris Pharmaceuticals, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Pieris Pharmaceuticals, Inc. stock fall?

The decline in Pieris Pharmaceuticals, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Pieris Pharmaceuticals, Inc. Forecast, price target & analysts

$138.16

5.42%

Nasdaq, Sep 25, 04:00 pm EDT. Closed.

ISIN

US7207951036

Symbol

PVLA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Pieris Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation

Pieris Pharmaceuticals, Inc. Classifications & Recommendation

Buy

95%

Hold

Pieris Pharmaceuticals, Inc. Price Target

Target Price	$233.58
Price	$138.16
Potential	69.06% register free of charge
Number of Estimates	18

	18 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2027 . The average Pieris Pharmaceuticals, Inc. target price is $233.58. This is 69.06% register free of charge higher than the current stock price. The highest price target is $283.50 105.20% register free of charge , the lowest is $207.05 49.86% register free of charge .
	A rating was issued by 22 analysts: 21 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2027 of 69.06% register free of charge . Most analysts recommend the Pieris Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
P/E		negative

18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast for earnings per share. The average Pieris Pharmaceuticals, Inc. EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2027	$-8.34 24.48% unlock
2028	$-5.41 35.13% unlock
2029	$5.98 210.54% unlock
2030	$23.51 293.14% unlock
2031	$41.62 77.03% unlock
2032	$47.13 13.24% unlock
2033	$59.33 25.89% unlock

Current
2026	-20.63 35.94% unlock
2027	-16.56 19.73% unlock
2028	-25.52 54.11% unlock
2029	23.09 190.48% unlock
2030	5.88 74.53% unlock
2031	3.32 43.54% unlock
2032	2.93 11.75% unlock
2033	2.33 20.48% unlock

Pieris Pharmaceuticals, Inc....

Current Pieris Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Chardan Capital	Locked ➜ Locked	Locked	Sep 21 2026
Stephens & Co.	Locked ➜ Locked	Locked	May 21 2026
Chardan Capital	Locked ➜ Locked	Locked	May 21 2026
Stephens & Co.	Locked ➜ Locked	Locked	May 12 2026
Chardan Capital	Locked ➜ Locked	Locked	Mar 31 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 24 2026
Chardan Capital	Locked ➜ Locked	Locked	Mar 16 2026

Analyst Rating	Date
Locked Chardan Capital: Locked ➜ Locked	Sep 21 2026
Locked Stephens & Co.: Locked ➜ Locked	May 21 2026
Locked Chardan Capital: Locked ➜ Locked	May 21 2026
Locked Stephens & Co.: Locked ➜ Locked	May 12 2026
Locked Chardan Capital: Locked ➜ Locked	Mar 31 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 24 2026
Locked Chardan Capital: Locked ➜ Locked	Mar 16 2026

Discover more stocks with a high price target

NIO ADR 104.57%

Alibaba Group Holding Ltd 70.15%

Rheinmetall 66.12%

Infineon 62.78%

Tencent Holdings Ltd. 56.53%

Adyen 53.79%

TUI 52.57%

Uber Technologies 47.97%

BYD 47.08%

Siemens Energy 46.63%

Adidas 42.38%

Deutsche Telekom 37.89%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now